NRIX - CIK 0001549595
The table below shows Nurix Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.19M | $78.44M | $84.26M | $75.92M | $99.04M | $116.79M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | $19.00M | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $554.39M |
| $440.60M |
| $515.33M |
| $563.70M |
| $456.04M |
| $450.22M |
| Property, plant & equipment | $21.70M | $20.50M | $18.77M | $18.45M | $17.07M | $18.56M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $636.13M | $522.47M | $591.55M | $615.04M | $513.60M | $511.03M |
| Accounts payable | $10.29M | $8.61M | $5.95M | $8.40M | $3.92M | $2.81M |
| Total current liabilities | $92.20M | $82.35M | $75.61M | $89.99M | $86.30M | $80.78M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $155.24M | $150.22M | $143.95M | $134.13M | $136.74M | $140.34M |
| Retained earnings | -$1.09B | -$925.00M | -$838.58M | -$795.12M | -$680.22M | -$631.26M |
| Total equity | $480.89M | $372.25M | $447.60M | $480.92M | $376.86M | $370.69M |